Secondary hyperoxaluria: a risk factor for kidney stone formation and renal failure in native kidneys and renal grafts

Karaolanis, Georgios; Lionaki, Sophia; Moris, Demetrios; Palla, Viktoria–Varvara; Vernadakis, Spiridon

doi:10.1016/j.trre.2014.05.004

Cited by 37 publications

(35 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dietary hyperoxaluria, as simulated by the current study, is well recognized as an important feature of recurrent kidney stones in several populations, including idiopathic stone formers, and in those with enteric hyperoxaluria related to various gastrointestinal pathologies, especially after Roux-en-Y bariatric surgery procedures [2,3,5,6]. In the more severely affected individuals, this may lead to oxalate nephropathy, which if progressive leads to CKD and end-stage renal disease that would require dialysis or kidney transplantation [7].…”

Section: Discussionmentioning

confidence: 99%

“…Additionally, methods of food preparation may affect the soluble oxalate content as well, such that even the same food prepared differently may yield different oxalate burdens to patients [20]. Importantly, even with dietary counseling and adherence to a recommended diet, many patients with hyperoxaluria after bariatric surgery, or with bowel disease, remain with hyperoxaluria and develop stones and CKD [6,21]. Other therapeutic approaches to reduce hyperoxaluria in patients with kidney stones have been evaluated.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, recent epidemiologic studies link kidney stone recurrence to the development of chronic kidney disease (CKD) [5]. Additional complications in some patients with secondary hyperoxaluria may include oxalate nephropathy, nephrocalcinosis and progression to end-stage renal disease and damage to the transplanted kidney if present [6,7,8]. …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A Double-Blind, Placebo Controlled, Randomized Phase 1 Cross-Over Study with ALLN-177, an Orally Administered Oxalate Degrading Enzyme

Langman

Grujić²,

Pease³

et al. 2016

Am J Nephrol

View full text Add to dashboard Cite

Background: Hyperoxaluria may result from increased endogenous production or overabsorption of dietary oxalate in the gastrointestinal tract leading to nephrolithiasis and, in some, to oxalate nephropathy and chronic kidney disease. ALLN-177 is an oral formulation of a recombinant, oxalate specific, microbial enzyme oxalate decarboxylase intended to treat secondary hyperoxaluria by degrading dietary oxalate in the gastrointestinal tract, thereby reducing its absorption and subsequent excretion in the urine. Methods: This double-blind, placebo controlled, randomized, cross-over, phase 1 study of ALLN-177 evaluated the tolerability of ALLN-177 and its effect on urinary oxalate excretion in 30 healthy volunteers with hyperoxaluria induced by ingestion of a high oxalate, low calcium (HOLC) diet. The primary end point was the difference in the mean 24-hour urinary oxalate excretion during the ALLN-177 treatment period compared with the placebo treatment period. Results: The daily urinary oxalate excretion increased in the study population from 27.2 ± 9.5 mg/day during screening to 80.8 ± 24.1 mg/day (mean ± SD) on the HOLC diet before introducing ALLN-177 or placebo therapy for 7 days. Compared to placebo, ALLN-177 treatment reduced urinary oxalate by 11.6 ± 2.7 mg/day, p = 0.0002 (least squares mean ± SD). Conclusions: In healthy volunteers, with diet-induced hyperoxaluria treatment with ALLN-177, when compared to placebo, significantly reduced urinary oxalate excretion by degrading dietary oxalate in the gastrointestinal tract and thereby reducing its absorption. ALLN-177 may represent a new approach for managing secondary hyperoxaluria and its complications.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Double-Blind, Placebo Controlled, Randomized Phase 1 Cross-Over Study with ALLN-177, an Orally Administered Oxalate Degrading Enzyme

Langman

Grujić²,

Pease³

et al. 2016

Am J Nephrol

View full text Add to dashboard Cite

show abstract

“…An intact colon is required for increased oxalate absorption via this mechanism [32] . This form of hyperoxaluria is seen in partial gastrectomy, bariatric surgery, jejunoileal bypass, and inflammatory bowel disease [7,33] .…”

Section: Hyperoxaluria Associated With Fat Malabsorptionmentioning

confidence: 99%

“…This test can help identify hyperabsorbers who would benefit from dietary interventions focusing on lowering oxalate and increasing calcium in the diet. This diagnostic test also helps to differentiate between primary and secondary forms of hyperoxaluria [33] . Radiological imaging may aid in diagnosis of mul tisystem involvement.…”

Section: Systemic Oxalosismentioning

confidence: 99%

Primary and secondary hyperoxaluria: Understanding the enigma

Bhasin

Ürekli

Atta

2015

WJN

150

125

View full text Add to dashboard Cite

show abstract

Inhibitors of Calcium Oxalate Crystallization for the Treatment of Oxalate Nephropathies

et al. 2020

View full text Add to dashboard Cite

Calcium oxalate (CaOx) crystal‐induced nephropathies comprise a range of kidney disorders, for which there are no efficient pharmacological treatments. Although CaOx crystallization inhibitors have been suggested as a therapeutic modality already decades ago, limited progress has been made in the discovery of potent molecules with efficacy in animal disease models. Herein, an image‐based machine learning approach to systematically screen chemically modified myo‐inositol hexakisphosphate (IP6) analogues is utilized, which enables the identification of a highly active divalent inositol phosphate molecule. To date, this is the first molecule shown to completely inhibit the crystallization process in the nanomolar range, reduce crystal–cell interactions, thereby preventing CaOx‐induced transcriptomic changes, and decrease renal CaOx deposition and kidney injury in a mouse model of hyperoxaluria. In conclusion, IP6 analogues based on such a scaffold may represent a new treatment option for CaOx nephropathies.

show abstract

Secondary hyperoxaluria: a risk factor for kidney stone formation and renal failure in native kidneys and renal grafts

Cited by 37 publications

References 83 publications

A Double-Blind, Placebo Controlled, Randomized Phase 1 Cross-Over Study with ALLN-177, an Orally Administered Oxalate Degrading Enzyme

A Double-Blind, Placebo Controlled, Randomized Phase 1 Cross-Over Study with ALLN-177, an Orally Administered Oxalate Degrading Enzyme

Primary and secondary hyperoxaluria: Understanding the enigma

Inhibitors of Calcium Oxalate Crystallization for the Treatment of Oxalate Nephropathies

Contact Info

Product

Resources

About